Pipeline Expands With Potential New Brain Cancer Treatment
Filed with ASX · · 4 pages · English
Story so far
Earlier from Noxopharm
- Approval to be sought for COVID-19 Clinical Study in U.S.
- Noxopharm Investigating Potential COVID-19 Treatment
- Veyonda Awarded First Allowed Patent Application
- LuPIN Prostate Cancer Trial Fully Recruited
- Half Year Accounts and Chairman Letter
Later from Noxopharm
- Abscopal Responses Achieved in Prostate Cancer
- Noxopharm March 2020 Quarterly Report & Appendix 4C
- $7.9 Million Fully Underwritten Entitlement Offer Announced
- Entitlement Offer Prospectus
- FDA allows Veyonda Pre-IND Submission for COVID-19
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm